Claims for Patent: 7,045,289

Summary for Patent: 7,045,289

Title:	Detection of RNA Sequences
Abstract:	The present invention provides novel cleavage agents and polymerases for the cleavage and modification of nucleic acid. The cleavage agents and polymerases find use, for example, for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. In some embodiments, the 5\' nuclease activity of a variety of enzymes is used to cleave a target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.
Inventor(s):	Allawi; Hatim (Madison, WI), Bartholomay; Christian Tor (Madison, WI), Chehak; LuAnne (Janesville, WI), Curtis; Michelle L. (Cottage Grove, WI), Eis; Peggy S. (San Diego, CA), Hall; Jeff G. (Madison, WI), Ip; Hon S. (Madison, WI), Kaiser; Michael (Madison, WI), Kwiatkowski, Jr.; Robert W. (Verona, WI), Lukowiak; Andrew A. (Stoughton, WI), Lyamichev; Victor (Madison, WI), Ma; WuPo (Madison, WI), Olson-Munoz; Marilyn C. (Madison, WI), Olson; Sarah M. (Cross Plains, WI), Schaefer; James J. (Madison, WI), Skrzypczynski; Zbigniew (Verona, WI), Takova; Tsetska Y. (Madison, WI), Vedvik; Kevin L. (Madison, WI), Lyamichev; Natalie (Madison, WI), Neri; Bruce P. (Carlsbad, CA)
Assignee:	Third Wave Technologies, Inc. (Madison, WI)
Application Number:	09/864,636
Patent Claims:	1. A method for detecting the presence of a target nucleic acid comprising: a) cleaving an invasive cleavage structure, said invasive cleavage structure comprising an RNA target nucleic acid; and b) detecting the cleavage of said invasive cleavage structure. 2. The method of claim 1, wherein cleaving is carried out by a cleavage agent. 3. The method of claim 1, wherein said target nucleic acid comprises a first region and a second region, said second region downstream of and contiguous to said first region. 4. The method of claim 3, wherein said invasive cleavage structure comprises said target nucleic acid, a first oligonucleotide, and a second oligonucleotide, wherein at least a portion of said first oligonucleotide is completely complementary to said first region of said first target nucleic acid, and wherein said second oligonucleotide comprises a 3' portion and a 5' portion, wherein said 5' portion is completely complementary to said second region of said target nucleic acid. 5. The method of claim 4, wherein at least said portion of said first oligonucleotide is annealed to said first region of said target nucleic acid and wherein at least said 5' portion of said second oligonucleotide is annealed to said second region of said target nucleic. 6. The method of claim 1, wherein said cleaving generates a non-target cleavage product. 7. The method of claim 6, wherein said detecting the cleavage of said invasive cleavage structure comprises detecting said non-target cleavage product. 8. The method of claim 4, wherein said 3' portion of said second oligonucleotide comprises a 3' terminal nucleotide not complementary to said target nucleic acid. 9. The method of claim 4, wherein said 3' portion of said second oligonucleotide consists of a single nucleotide not complementary to said target nucleic acid. 10. The method of claim 1, wherein said detecting the cleavage of said invasive cleavage structure comprises detection of fluorescence. 11. The method of claim 1, wherein said detecting the cleavage of said invasive cleavage structure comprises detection of mass. 12. The method of claim 1, wherein said detecting the cleavage of said invasive cleavage structure comprises detection of fluorescence energy transfer. 13. The method of claim 1, wherein said detecting the cleavage of said cleavage structure comprises detection selected from the group consisting of detection of radioactivity, luminescence, phosphorescence, fluorescence polarization, and charge. 14. The method of claim 4, wherein said first oligonucleotide is attached to a solid support. 15. The method of claim 4, wherein said second oligonucleotide is attached to a solid support. 16. The method of claim 2, wherein said cleavage agent comprises a structure-specific nuclease. 17. The method of claim 16, wherein said structure-specific nuclease comprises a thermostable structure-specific nuclease. 18. The method of claim 2, wherein said cleavage agent comprises an enzyme, wherein said enzyme comprises a heterologous functional domain, wherein said heterologous functional domain provides altered functionality in a nucleic acid cleavage assay. 19. The method of claim 18, wherein said enzyme comprises a 5' nuclease. 20. The method of claim 19, wherein said 5' nuclease comprises a thermostable 5' nuclease. 21. The method of claim 18, wherein said enzyme comprises a polymerase. 22. The method of claim 21, wherein said polymerase is altered in sequence relative to a naturally occurring sequence of a polymerase such that it exhibits reduced DNA synthetic activity from that of the naturally occurring polymerase. 23. The method of claim 21, wherein said polymerase comprises a thermostable polymerase. 24. The method of claim 23, wherein said thermostable polymerase comprises a polymerase from a Thermus species. 25. The method of claim 23, wherein said Thermus species is selected from Thermus aquaticus, Thermus flavus, Thermus thermophilus, Thermus filiformus, and Thermus scotoductus. 26. The method of claim 18, wherein said heterologous functional domain comprises an amino acid sequence that provides an improved nuclease activity in said nucleic acid cleavage assay. 27. The method of claim 18, wherein said heterologous functional domain comprises an amino acid sequence that provides an improved substrate binding activity in said nucleic acid cleavage assay. 28. The method of claim 18, wherein said heterologous functional domain comprises an amino acid sequence that provides improved background specificity in said nucleic acid cleavage assay. 29. The method of claim 18, wherein said heterologous functional domain comprises two or more amino acids from a polymerase domain of a polymerase. 30. The method of claim 29, wherein at least one of said two or more amino acids is from a palm region of said polymerase domain. 31. The method of claim 29, wherein at least one of said two or more amino acids is from a thumb region of said polymerase domain. 32. The method of claim 29, wherein said polymerase comprises Thermus thermophilus polymerase. 33. The method of claim 29, wherein said two or more amino acids from said polymerase domain comprise two or more amino acids from amino acids 300-650 of SEQ ID NO:1. 34. The method of claim 6, further comprising the steps of forming a second invasive cleavage structure comprising said non-target cleavage product and cleaving said second invasive cleavage structure. 35. The method of claim 3, wherein a portion of said target nucleic acid consisting of said first region and said second region of said target nucleic acid comprises a splice junction. 36. The method of claim 3, wherein said first region or said second region of said target nucleic acid comprises an exon. 37. The method of claim 3, wherein said first region or said second region of said target nucleic acid comprises an intron. 38. The method of claim 1, wherein said RNA target nucleic acid is provided in a cell lysate. 39. The method of claim 4, wherein said first oligonucleotide is covalently attached to said second oligonucleotide.

Details for Patent 7,045,289

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-01-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-01-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-01-24